FMP
Baxter International Inc.
BAX
NYSE
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
30.9 USD
-0.3 (-0.971%)
Mr. David Brent Shafer
Healthcare
Medical - Instruments & Supplies
NYSE
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused i...
0000010456
US0718131099
071813109
One Baxter Parkway
224 948 2000
US
38,000
Oct 27, 1981
0000010456
NYSE
Medical - Instrument...
Healthcare
071813109
US0718131099
US
30.9
0.63
5.03M
15.86B
-
26.25-40.49
22.09
-
-
-
-
-59.42
-
https://www.baxter.com
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Stuart Mooney
May 1, 2025
Baxter International Inc. (NYSE:BAX) is a prominent player in the global medtech industry, known for its innovative medical devices and solutions. The company specializes in products like intravenous (IV) solutions and patient-monitoring systems, which have been in high demand. Baxter's strong market presence is reflected in its recent financial performance, where it exceeded Wall Street expectations. On May 1, 2025, Baxter reported earnings per share (EPS) of $0.623, surpassing the estimated $...
Davit Kirakosyan
Feb 20, 2025
Baxter International (NYSE:BAX) surged over 8% intra-day today after delivering better-than-expected fourth-quarter results, driven by strong sales in its Pharmaceuticals and Medical Products & Therapies divisions. For Q4, the medical technology company posted adjusted earnings per share of $0.58, exceeding the $0.52 consensus estimate. Revenue reached $2.75 billion, beating forecasts of $2.67 billion and marking a 1% year-over-year increase on a reported basis and 2% growth at constant currency...
Andrew Wynn
Feb 20, 2025
Baxter International Inc. (NYSE:BAX) is a global healthcare company that provides a broad portfolio of essential medical products, including infusion therapies, pharmaceuticals, and patient support systems. The company is set to release its quarterly earnings on February 20, 2025. Analysts expect an earnings per share (EPS) of $0.81 and revenue of approximately $2.67 billion. Baxter has a history of surpassing earnings expectations, with an average surprise of 3.62% over the past four quarters....
Forbes
Aug 19, 2024
On August 13, 2024, Baxter International Inc. (NYSE: BAX, $36.12, Market Capitalization: $18.4 billion), a global medtech leader, and funds managed by global investment firm Carlyle (NASDAQ: CG) announced that they have signed a definitive agreement under which Carlyle will acquire Baxter's Kidney Care segment, to be named Vantive, for $3.8 billion (For details refer to spinoffresearch.com). Under the terms of the definitive agreement, subject to certain closing adjustments, Baxter will receive ...
Seeking Alpha
Aug 17, 2024
The focus of this article is to provide a select list of 10 dividend stocks that, in our view, are currently undervalued and should provide an average of 4.5% plus yield for the foreseeable future. We use a simple and easy-to-implement filtering method to narrow down our list to probable candidates. In our view, these dividend stocks will provide sustainable yields with decent dividend growth that will likely meet and exceed the rate of inflation.
Zacks Investment Research
Aug 14, 2024
Baxter (BAX) announces the divestiture of its Kidney Care segment, Vantive, to a global investment firm Carlyle.
Zacks Investment Research
Aug 14, 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Investopedia
Aug 13, 2024
Shares of Baxter International (BAX) fell Tuesday after the company said it would sell its kidney treatment division to The Carlyle Group (CG) for $3.8 billion in cash.